# US 2013/0252894 A1 · Sustained delivery of exenatide and other polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252894 A1
- Document ID: US20130252894A1
- Status: Published application
- Kind: A1
- Application number: 13/897,895
- Filed: 2013-05-20
- Published: 2013-09-26
- Earliest claimed: 2008-06-25
- Assignees: Endo Pharmaceuticals Solutions Inc.
- Applicants: Endo Pharmaceuticals Solutions Inc.
- Inventors: Petr Kuzma; Stefanie Decker; Harry Quandt
- Web page: https://patentgrep.com/patent/US20130252894A1

## CPC

- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/26: Glucagons
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.

## Claims

### Claim 1

A method of manufacturing an implantable device, wherein the implantable device can deliver a therapeutic polypeptide agent to a subject, and the release of the therapeutic polypeptide agent from the implantable device can be modulated by varying the components or the amounts of the components of the implantable device, the method comprising: a) mixing one or more polymerizable monomeric substances; b) adding one or more substances selected from the group consisting of: an excipient, a wetting agent, a non-ionic surfactant, an organic solvent, an alcohol, a reducing agent, an oxidizing agent and an aqueous solvent; and c) subjecting the mixture to conditions that cause the one or more polymerizable monomeric substances to polymerize in the presence of the one or more components, thereby forming the implantable device.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more polymerizable monomeric substances comprises one or more compounds selected from the group consisting of: 2-hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, and trimethylolpropane trimethacrylate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mixture further comprises one or more components selected from the group consisting of: benzoin methyl ether, Perkadox 16, and isopropyl alcohol.

### Claim 4 (depends on 1)

The method of claim 1, wherein the rate of release of the therapeutic polypeptide can be modulated.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mixture is placed into a mold prior to being subjected to a polymerization step.

### Claim 6 (depends on 5)

The method of claim 5, wherein the polymerization step is initiated by ultraviolet irradiation.

### Claim 7 (depends on 1)

The method of claim 1, further comprising charging the implantable device with a desired amount of a therapeutic polypeptide agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutic polypeptide agent comprises a GLP-1 analog.

### Claim 9 (depends on 8)

The method of claim 8, wherein the GLP-1 analog comprises exenatide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutic polypeptide agent is combined with a wetting agent to form a solid formulation prior to being charged into the implantable device.

### Claim 11 (depends on 1)

The method of claim 1, wherein the solid formulation comprises about 98% exenatide and about 2% stearic acid.

### Claim 12 (depends on 1)

The method of claim 1, wherein the mixture comprises a mixture selected from the group consisting of: a) about 78.72% HEMA, about 0.40% EGDMA, about 0.79% Vitamin E TDGS, about 0.24% BME, about 0.08% P-16, about 9.89% water and about 9.89% isopropyl alcohol; b) about 78.72% HEMA, about 0.40% EGDMA, about 0.79% Vitamin E TDGS, about 0.24% BME, about 0.08% P-16 and about 19.78% water; c) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.07% P-16, about 14.85% water and about 14.85% isopropyl alcohol; and d) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.07% P-16 and about 29.71%.
